The case for pneumococcal vaccination of infantsNovember 08, 2005Although the Canadian National Advisory Committee on Immunization recommends that children receive the new pneumococcal vaccine PCV7 beginning at 2 months of age, provincial implementation of the recommendation has been slow. The vaccine protects against infections that result in pneumonia, otitis media, meningitis and other diseases. In Alberta, however, the vaccine is a publicly funded service. This report of the experience with the vaccine in the greater Calgary region shows 2 important results. First, rates of severe infection due to Streptococcus pneumoniae (the causative agent and target of the vaccine) have fallen dramatically among children, especially for the 7 common varieties of S. pneumoniae that are covered by the vaccine. Second, there is a spillover effect among adults over 65 years of age (for whom a similar vaccine is recommended and widely used in Alberta): rates of invasive infections due to the 7 serotypes of S. pneumoniae covered by the child vaccine have also fallen. Canadian Medical Association Journal |
|||||||||||||||||||||
| Related Pneumococcal Current Events and Pneumococcal News Articles Inappropriate sepsis therapy leads to fivefold reduction in survival Patients experiencing septic shock who receive inappropriate therapy may have a fivefold reduction in survival, shows a new study. Scientists create NICE solution to pneumonia vaccine testing problems Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB). Review: Pneumococcal conjugate vaccines effective at preventing child deaths A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths. New WHO data underscores global threat of the world's leading child killer New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries. New vaccine shows promise for COPD patients at risk for pneumonia A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society. How meningitis bacteria attack the brain A specific protein on the surface of a common bacterial pathogen allows the bacteria to leave the bloodstream and enter the brain, initiating the deadly infection known as meningitis. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. Statins don't lower risk of pneumonia in elderly Taking popular cholesterol-lowering statin drugs, such as Lipitor® (atorvastatin), does not lower the risk of pneumonia. From poison to prevention One of the major challenges in modern vaccinology is to engineer vectors that are highly infectious, yet don't cause illness. Trickier still is to ensure that such weapons against infectious disease can be safely disarmed, once their immunogenic work is done. Pneumococcal vaccine does not appear to protect against pneumonia Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia. More Pneumococcal Current Events and Pneumococcal News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||